Improving clinical management of heart disease from early detection to treatment

IHI call 7 – topic 1

Klelia Salpea, PhD
10/01/2024 • Online
Before we start…

- We are recording this webinar and it will be published on the IHI website and B2Match platform.

- We will also publish the presentation slides.

- The call will be officially launched next week and all links and details of how to apply will be published on the IHI website and the Funding and Tenders Portal.
Today’s session

Will cover:
- Introduction to IHI programme
- IHI call topic
  - Challenge, need for public-private collaborative research
  - Scope, outcomes & impacts, budget
- Proposal submission, evaluation & preparation tips

Will not cover
- rules and procedures
- how to prepare the financial proposal
Innovative Health Initiative

EU partnership in health between:
● the European Union represented by the European Commission &
● Healthcare industry associations:
  ● COCIR (medical imaging, radiotherapy, health ICT and electromedical industries)
  ● EFPIA, including Vaccines Europe (pharmaceutical and vaccine industries)
  ● EuropaBio (biotechnology industry)
  ● MedTech Europe (medical technology industry)
IHI’s general objectives

● Turn health research and innovation into real benefits for patients and society

● Deliver safe, effective health innovations that cover the entire spectrum of care – from prevention to diagnosis and treatment – particularly in areas where there is an unmet public health need

● Make Europe’s health industries globally competitive.
Strategic Research & Innovation Agenda

Focus

● **Cross-sectoral approaches** to facilitate creation of new products and services to prevent, intercept, diagnose, treat and manage diseases and foster recovery more efficiently.

Goal

● Lay foundations for development of safer and more effective health care products or solutions that respond to unmet public health needs and that can be implemented into healthcare systems.

Research supported by IHI should remain at precompetitive level

IHI projects are...

- Created via open and competitive calls for proposals

- Cross-sectorial public private partnerships leveraging:
  - Contributions from industrial partners from the IHI industry associations (COCIR, EFPIA including Vaccines Europe, EuropaBio, MedTechEurope)
  - if relevant, contributions from contributing partners (must be approved by IHI GB)
    and
  - Public funding via European Commission (Horizon Europe)
How does IHI work? Single-stage procedure

Call Launch

Proposal Submission
- Private partners
- Academics
- Contributing partners
- SMEs
- Health care professionals
- Regulators
- Patient organisations
- HTA bodies

Consortia form & write proposals

Competitive Evaluation

Project Launch

Grant preparation, signature & project start
Improving clinical management of heart disease from early detection to treatment

IHI call 7 – topic 1
The challenge

- Heart diseases (SHD/CAD/HF/heart arrhythmias) are causing a high burden in Europe and worldwide.
- Their prevalence is expected to rise due to the ageing population and the lifestyle of citizens in Europe.
- Disease management and long-term outcomes remain heterogeneous due to lack of comprehensive access to detection, diagnosis and care.

*Innovative Health Initiative*

Better integration of the different steps of care from primary to hospital care for an optimised disease management in more efficient healthcare settings.
Need for public-private, cross-sector collaboration

The complexity of clinical care for heart disease patients requires bringing together:

**Industry partners**
- Diagnosis
- Data analytics
- Clinical decision-making
- Pharmaceutical interventions
- Non-pharmaceutical interventions
- .............

**Public partners**
- Researchers
- Hospitals
- Health care professionals
- Patients
- Patient organisations
- Regulators
- .............
Scope of the topic (1/3)

Address the need to optimise heart disease management in more efficient healthcare settings

- Applicants may identify and address only some critical aspects of the patients’ journey or specific care settings, with the aim of contributing to the overall care pathway improvement.
- Applicants should address all or any of the following heart diseases: SHD, CAD, HF, and heart arrhythmias.
## Scope of the topic (2/3)

### OBJECTIVES

1. **Optimise the patient pathway and the transition among the teams from one to the other care setting**

2. **Improve patient outcomes through earlier detection, better diagnosis, monitoring and/or treatment**

3. **Develop and implement measures and digital tools to enhance efficiency in primary and hospital care (e.g. reducing hospitalisations and/or length of stay), and guide patients faster to the selection of the best treatment modality**

4. **Develop personalised, patient-centric solutions in diagnosis and treatment considering specific populations’ needs**

5. **Consider the sustainability and scalability of the proposed solutions**
Scope of the topic (3/3)

OBJECTIVES

VI. Explore management strategies combining access to medical teams specialising in heart disease and social interventions to address population inequalities in outcomes

VII. Conduct an initial health economic study of the proposed interventions on the healthcare system

VIII. Engage patients and healthcare professionals in all stages of the project from conceptualisation and throughout the implementation.

IX. Consider the potential regulatory impact of the results and develop a regulatory strategy for generating appropriate evidence and engaging with regulators in a timely manner
Expected outcomes

Healthcare systems and patients: development of integrated solutions for improving critical aspects in the overall care pathway for heart disease.

Healthcare systems and patients: development or optimisation of innovative technologies leading to personalised, patient-centric solutions for the early detection, diagnosis or treatment of heart disease.

Patients: strategies tailored to their needs for improved outcomes in heart disease.

Healthcare professionals: deployment of solutions for improved diagnostic procedures, referral programs or clinical workflows as well as targeted training for relevant clinical staff where appropriate.
Expected impacts

**Patients:** personalised patient-centred healthcare, improved patient outcomes and experience throughout the continuum of care.

**Healthcare professionals:**
- novel diagnostic procedures and optimised clinical workflows
- enhancement of existing clinical management guidelines and the development of new ones as appropriate.

**Healthcare systems:** organisational solutions and an efficient transition through the different stages along the whole continuum of the care pathway for heart disease.

**Companies:** develop and offer advanced, robust and scalable solutions that leverage innovative technologies, tools and services allowing for integration with other existing workflows.
Dissemination, exploitation & communication

- **Reserve budget** for effective dissemination, exploitation & communication
- **Describe the dissemination, exploitation and communication measures** that are planned, and the target group(s) addressed, in particular:
  - Encourage the uptake of the results of the project through a strong communication and outreach plan
  - Allocating appropriate resources to explore synergies with other relevant initiatives and projects
  - Elements in line with the Availability, Accessibility and Affordability (3A) provisions
Budget

IHI financial contribution: EUR 12.5 million

Industry / CP contribution: EUR 12.5 million *

Project budget: EUR 25 million

* At least 45% of the project budget must be covered by contributions from project participants

Total available IHI budget for this topic: EUR 25 million
## Simplified budget example

### Single-stage calls for proposals

<table>
<thead>
<tr>
<th>Type of participant</th>
<th>Total eligible costs + IKAA</th>
<th>Funding rate</th>
<th>Reimbursed eligible costs</th>
<th>Contributions (IKOP, FC, IKAA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>‘Public partners’</td>
<td>15 million</td>
<td>100%</td>
<td>15 million</td>
<td>0</td>
</tr>
<tr>
<td>(Universities, hospitals, SMEs, patient orgs, regulators..)</td>
<td>(full costs reimbursed, cannot contribute IKOP/IKAA/FC)</td>
<td>15 million</td>
<td>100%</td>
<td>15 million</td>
</tr>
<tr>
<td>Private members &amp; contributing partners</td>
<td>15 million</td>
<td>100%</td>
<td>0</td>
<td>15 million</td>
</tr>
<tr>
<td>(contribute IKOP/IKAA/FC, no costs reimbursed)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Private members &amp; contributing partners (‘Hybrid’)</td>
<td>10 million</td>
<td>100%</td>
<td>5 million</td>
<td>5 million</td>
</tr>
<tr>
<td>(costs reimbursed and contribute IKOP/IKAA/FC)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>40 million</td>
<td>100%</td>
<td>20 million (50%) Public funds</td>
<td>20 million (50%) Private funds</td>
</tr>
</tbody>
</table>
Proposal submission & evaluation
Proposal Template - Parts A, B & Annexes

● **Part A** of the proposal is **administrative data** that is entered in webforms through the Funding & Tenders Portal.

● **Part B** of the proposal is the **narrative part** that includes three sections:
  ● Excellence
  ● Impact
  ● Quality and efficiency of the implementation

● **Read instructions** in proposal template **very carefully**

● **Annexes:**
  ● Participant type
  ● Budget details
  ● Clinical studies template
Evaluation Criteria (1/2)

● **Excellence**
  ● Clarity and pertinence of the project’s objectives, and the extent to which the proposed work is ambitious, and goes beyond the state of the art.
  ● Soundness of the proposed methodology, including the underlying concepts, models, assumptions, interdisciplinary approaches, appropriate consideration of the gender dimension in research and innovation content, and the quality of open science practices, including sharing and management of research outputs and engagement of citizens, civil society and end users where appropriate.

● **Impact**
  ● Credibility of the pathways to achieve the expected outcomes and impacts specified in the work programme, and the likely scale and significance of the contributions due to the project.
  ● Suitability and quality of the measures to maximise expected outcomes and impacts, as set out in the dissemination and exploitation plan, including communication activities.
Evaluation Criteria (2/2)

● **Quality and efficiency of the implementation**
  ● Quality and effectiveness of the work plan, assessment of risks, and appropriateness of the effort assigned to work packages, and the resources overall
  ● Capacity and role of each participant, and extent to which the consortium as a whole brings together the necessary expertise.
  ● Clearly defined and effective integration of in-kind and financial contributions, including those of IHI JU private members, their constituent or affiliated entities to enable a successful public-private partnership.
Tips for applicants
Tips for applicants

● Read all the call-relevant material, especially the **topic text**
  ● [www.ihi.europa.eu/apply-funding/open-calls](http://www.ihi.europa.eu/apply-funding/open-calls)

● Form your consortium **early**
  ● Always think “public-private partnership“
  ● Include partners bringing **in-kind contributions**

● Ensure that **all information requested in the call text and proposal template** is provided to allow the evaluation experts to easily assess your proposal against the evaluation criteria

● Consider & plan for the potential **regulatory impact** of results
Finding project partners

You’ll need to build or join a consortium!

● Network with your contacts & IHI Call Days participants:
  ● https://ihi-call-days.ihi.b2match.io/
  ● Use EU Funding & Tenders portal partner search tool:
    ● https://europa.eu/!QU87Nx
● Get in touch with your IHI national contact point:
  ● https://europa.eu/!D7jyMy
● Network on social media:
  ● www.twitter.com/IHIEurope
  ● be.linkedin.com/company/innovative-health-initiative
#IHICallDays

## Call 6
- **15 Jan**: 14:30 Rules & procedures: two-stage calls
- **16 Jan**: 10:30 RWD / RWE in decision-making
- **16 Jan**: 14:30 Treatment persistency

## Call 7
- **10 Jan**: 10:30 Management of heart disease
- **10 Jan**: 14:30 Optimised hospital workflows
- **11 Jan**: 10:30 Rules & procedures: single-stage calls
- **11 Jan**: 14:30 Clinical validation of biomarkers
- **12 Jan**: 14:30 Single-stage calls: financial aspects
- **23 Jan**: 14:30 Management of heart disease
- **24 Jan**: 14:30 Optimised hospital workflows
- **25 Jan**: 14:30 Clinical validation of biomarkers
Join the call 7 pitching sessions

23 Jan  14:30 Management of heart disease
24 Jan  14:30 Optimised hospital workflows
25 Jan  14:30 Clinical validation of biomarkers

Want to pitch?

✓ Indicate this in your profile by 12 January
✓ Register for the pitching session for your topic
✓ Create a participant profile and marketplace
✓ Download the slide template from the IHI Call Days portal and send us your presentation by 19 January
Questions

If you want to ask a question please use the chat function on the right corner of your screen.
Marketplace

1. Marketplace

2. Opportunities found

3. Call Topics
   - Improved prediction, detection, and treatment approaches for comprehensive stroke management (36)

4. Project Cooperation
   - EEG based Triage of Stroke Patients
     - What type of organisation are you looking for? (Question for consortium/coordinator seeking partners)
     - What kind of expertise are you looking for? (Question for consortium/coordinator seeking partners)
   - Medical image analysis and segmentation
     - We would like to join a consortium and can contribute the following expertise:
     - Medical image data are used in a variety of ways for diagnosis, treatment planning, monitoring of interventions, observation of condition changes and documentation. Common image modalities range from...
   - Remote vital functions monitoring, evaluation and smart interventions
     - Our research center focuses on the collection, remote monitoring, and evaluation of vital data.
     - What do we bring to the consortium?
How to book your meetings via the B2Match platform

Book your meetings in 4 easy steps

1. Make yourself available
2. Look for partner on the participants tab
3. Select date, time, attendees (up to eight per meeting), add message
4. Send the meeting request and wait for the reply

Step by Step guide on how to book meetings: https://europa.eu/lfnJFFM
Questions

If you want to ask a question please use the chat function on the right corner of your screen.
Thank you for your attention
Additional Slides
Dissemination, exploitation & communication

- Importance to communicate and disseminate results throughout the full lifespan of the project
- Plan Dissemination & Exploitation measures to maximise the impact
- Plan communication measures for promoting the project and its findings
- Short description of the Dissemination, Exploitation & Communication (D, E & C) activities, together with the impact pathways in the proposal. This is an admissibility condition.
- Full-fledged D, E & C plan to be submitted as a deliverable after the first 6 months of the project.
### SPECIFIC NEEDS
What are the specific needs that triggered this project?

**Example 1**
Health solutions need to be better tailored to patients' needs. Novel approaches are needed to capture patients' needs and to involve them in the development of a novel health technology.

### EXPECTED RESULTS
What do you expect to generate by the end of the project?

**Example 1**

- **Patient-centric clinical development:** Patients' perspectives included in design of studies.
- **Patients' perspective incorporated into the evidence generated for decision making.**

### D & E & C MEASURES
What dissemination, exploitation and communication measures will you apply to the results?

**Example 1**

- **Exploitation:** Approach to include patients' perspectives is adopted by industry in their novel health technologies development programmes.
- **Dissemination towards the scientific community and industry:** Scientific publication of the results of the demonstration pilot
- **Communication towards citizens:** An event in a shopping mall to show how the outcomes of the action are relevant to our everyday lives.

### TARGET GROUPS
Who will use or further up-take the results of the project? Who will benefit from the results of the project?

**Example 1**

- **Healthcare industry companies:** pharmaceutical (including vaccine), biopharmaceutical, medical (and digital) technologies, etc.
- **Scientific community:** clinical research investigations, and testing activities of health solutions
- **End-user of the novel health technology:** patients and citizens

### OUTCOMES
What change do you expect to see after successful dissemination and exploitation of project results to the target group(s)?

**Example 1**

- **Healthcare industry partners:** novel health technologies adapted to patients' needs.
- **Use of the scientific results published (measured through the bibliometric indicators of the project publication).**

### IMPACTS
What are the expected wider scientific, economic and societal effects of the project contributing to the expected impacts outlined in the topic text?

**Example 1**

- **Scientific:** New approach to patient engagement in the development of novel health technologies tailored to the patients' needs.
- **Economic/Technological:** Health solutions designed with the patients in mind will facilitate the adoption of the health technology by the market / healthcare system
- **Societal:** Patients will benefit from truly patient-centric health technologies (designed from the start based on their needs)